Cardiff Oncology Inc (NASDAQ: CRDF) Is Rated A Buy By Analysts.

In the last trading session, 2.16 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.96. With the company’s per share price at $4.59 changed hands at -$0.69 or -13.07% during last session, the market valuation stood at $205.08M. CRDF’s last price was a discount, traded about -39.87% off its 52-week high of $6.42. The share price had its 52-week low at $0.94, which suggests the last value was 79.52% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 3-month average coming to 1.75 million.

Cardiff Oncology Inc (NASDAQ:CRDF) trade information

Instantly CRDF was in red as seen at the end of in last trading. With action -18.90%, the performance over the past five days has been red. The drop to weekly highs of 5.98 subtracted -13.07% to the stock’s daily price. The company’s shares are showing year-to-date upside of 210.14%, with the 5-day performance at -18.90% in the red. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is -8.75% down.

Cardiff Oncology Inc (CRDF) estimates and forecasts

Data shows that the Cardiff Oncology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 313.51% over the past 6 months, a -5.38% in annual growth rate that is considerably lower than the industry average of 13.10%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.42%. The 2024 estimates are for Cardiff Oncology Inc earnings to decrease by -4.78%.